


**Tchaikapharma High Quality Medicines Inc.**  
**Consolidated Statement of financial position**  
as of 31 March 2023


	31.03.2023	31.12.2022
	BGN'000	BGN'000
<b>Non-current assets</b>		
Property, plant and equipment	34,834	35,319
Intangible Assets and Goodwill	3,694	3,761
Trade receivables	5,076	5,076
<b>Non-current assets</b>	<b>43,604</b>	<b>44,156</b>
Inventories	12,383	13,480
Trade and other receivables	64,510	62,056
Current tax assets	27	27
Cash and cash equivalents	98	142
<b>Current Assets</b>	<b>77,018</b>	<b>75,705</b>
<b>Assets</b>	<b>120,622</b>	<b>119,861</b>
Issued capital	84,500	84,500
Statutory reserve	12,498	12,498
Retained earnings	6,526	4,587
<b>Equity</b>	<b>103,524</b>	<b>101,585</b>
<i>Equity Attributable to owners of the parent company</i>	<i>103,524</i>	<i>101,585</i>
<i>Non-controlling interest in equity</i>	<i>-</i>	<i>-</i>
Long term borrowings	, 291	1,399
Deferred tax liabilities	1,042	1,042
Non-current provisions for employee benefits	191	191
<b>Non-current liabilities</b>	<b>2,524</b>	<b>2,632</b>
Trade and other payables	3,773	5,080
Short term borrowings	10,334	10,405
Current tax liabilities	467	159
<b>Current liabilities</b>	<b>14,574</b>	<b>15,644</b>
<b>Liabilities</b>	<b>17,098</b>	<b>18,276</b>
<b>Equity and liabilities</b>	<b>120,622</b>	<b>119,861</b>

Date of preparation: 29.05.2023

Executive director:

  
Biser Georgiev

Prepared by:

  
Petya Moneva

**Tchaikapharma High Quality Medicines Inc.**  
**Consolidated statement of comprehensive income**  
**as 31 March 2023**


	<b>31.03.2023</b>	<b>31.03.2022</b>
	<b>BGN'000</b>	<b>BGN'000</b>
Revenue	13,610	12,778
Other income	30	54
<b>Total income</b>	<b>13,640</b>	<b>12,832</b>
Carrying amount of goods sold	(709)	(102)
Changes in inventories of finished products and work in progress	(257)	(560)
Materials and services	(7,573)	(7,735)
Personnel expenses	(1,567)	(1,371)
Depreciation / amortisation expenses	(867)	(940)
Other expenses	(468)	(73)
Finance income	27	5
Finance costs	(147)	(89)
<b>Total expenses</b>	<b>(11,561)</b>	<b>(10,865)</b>
<b>Profit Loss before tax</b>	<b>2,079</b>	<b>1,967</b>
Current tax expense income	(140)	(90)
<b>Profit Loss</b>	<b>1,939</b>	<b>1,877</b>
<i>Profit Loss attributable to owners of the parent company</i>	<i>1,939</i>	<i>1,877</i>
<i>Profit Loss attributable to non-controlling interests</i>	<i>-</i>	<i>-</i>
<b>Other comprehensive income</b>	<b>1,939</b>	<b>1,877</b>
<i>Profit Loss attributable to owners of the parent company</i>		
<i>Profit Loss attributable to non-controlling interests</i>		
<b>Comprehensive income</b>	<b>1,939</b>	<b>1,877</b>
<i>Profit Loss attributable to owners of the parent company</i>	<i>1,939</i>	<i>1,877</i>
<i>Profit Loss attributable to non-controlling interests</i>	<i>-</i>	<i>-</i>
Earnings per share / in BGN per 1 share /	0.02	0.02

Date of preparation: 29.05.2023

Executive director:

  
Biser Georgiev

Prepared by:

  
Petya Moneva

**Tchaikapharma High Quality Medicines Inc.**  
**Consolidated Cash flow statement**  
**as of 31 March 2023**

	<b>31.03.2023</b>	<b>31.03.2022</b>
	<b>BGN'000</b>	<b>BGN'000</b>
<b>Cash flows from operating activities</b>		
Receipts from sales of goods and rendering of services	8,489	7,570
Payments to suppliers for goods and services	(4,348)	(4,498)
Payments to and on behalf of employees	(1,593)	(1,343)
Income taxes paid classified as operating activities	(140)	(90)
Other cash payments from operating activities	(1,514)	(1,091)
<b>Cash flows from used in operating activities</b>	<b>894</b>	<b>548</b>
 <b>Cash flows from investing activities</b>		
Purchase of other longterm assets classified as investing activities	(699)	(361)
<b>Cash flows from used in investing activities</b>	<b>(699)</b>	<b>(361)</b>
 <b>Cash flows from financial activities</b>		
Dividends paid classified as financing activities	101	49
Proceeds from borrowings classified as financing activities	(109)	(49)
Repayments of borrowings classified as financing activities	(101)	(49)
Payments of lease liabilities classified as financing activities	(130)	(130)
<b>Cash flows from used in financial activities</b>	<b>(239)</b>	<b>(179)</b>
 <b>Increase/Decrease in cash and cash equivalents</b>	<b>(44)</b>	<b>8</b>
<b>Cash and cash equivalents</b>	<b>142</b>	<b>57</b>
<b>Cash and cash equivalents</b>	<b>98</b>	<b>65</b>

Date of preparation: 29.05.2023

Executive director:

Biser Georgiev

Prepared by:

Petya Moneva

**Tchaikapharma High Quality Medicines Inc.**  
**Consolidated statement on changes in equity**  
**as of 31 March 2023**


	Property plant and equipment revaluati on	Other reserves	Retained earnings	Equity abstract	Equity Attributab le to owners of the parent company	Non- controllin g interest in equity	
	Issued capital						
	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	
<b>Balance as of 01.01.2022</b>	<b>84,500</b>	<b>4,375</b>	<b>8,007</b>	<b>1,937</b>	<b>98,819</b>	<b>98,819</b>	-
Profit Loss	-	-	-	2,790	2,790	2,790	-
Other comprehensive income	-	(24)	-	-	-	-	-
<b>Comprehensive income</b>	-	<b>(24)</b>	-	<b>2,790</b>	<b>2,766</b>	<b>2,766</b>	-
Increase/Decrease through appropriation of retained earnings	-	-	140	(140)	-	-	-
<b>Total income expense</b>	-	-	<b>140</b>	<b>(140)</b>	-	-	-
<b>Balance as of 31.12.2022</b>	<b>84,500</b>	<b>4,351</b>	<b>8,147</b>	<b>4,587</b>	<b>101,585</b>	<b>101,585</b>	-
<b>Balance as of 01.01.2023</b>	<b>84,500</b>	<b>4,351</b>	<b>8,147</b>	<b>4,587</b>	<b>101,585</b>	<b>101,585</b>	-
Profit Loss	-	-	-	1,939	1,939	1,939	-
Other comprehensive income	-	-	-	-	-	-	-
<b>Comprehensive income</b>	-	-	-	<b>1,939</b>	<b>1,939</b>	<b>1,939</b>	-
Increase/Decrease through appropriation of retained earnings	-	-	-	-	-	-	-
<b>Total income expense</b>	-	-	-	-	-	-	-
<b>Balance as of 31.03.2023</b>	<b>84,500</b>	<b>4,351</b>	<b>8,147</b>	<b>6,526</b>	<b>103,524</b>	<b>103,524</b>	-

Date of preparation: 29.05.2023

Executive director:

  
Biser Georgiev

Prepared by:

  
Petya Moneva